A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

Vir Biotech begins patient dosing in phase 1 trial of EGFR-targeting PRO-XTEN dual-masked T-cell engager VIR-5525 to treat solid tumours: San Francisco Saturday, July 26, 2025, 12 ...

Gilead Sciences ( ($GILD) ) has risen by 7.31%. Read on to learn why. Gilead Sciences has seen a notable increase in its ...